Ads
related to: belimumab activating factor- Risks And Side Effects
Read The Potential Risks & Common
Side Effects That May Occur.
- Dosing & Admin Info
Learn About Dosing & Administration
And Find Helpful Resources & Info.
- Savings & Coverage
See If You Qualify For Savings And
Understand Your Coverage Options.
- BENLYSTA Cares
Talk To Trained Nurses Live To Ask
Questions About The Medication Now.
- BENLYSTA Information
Find Injection Training Resources
On The Official Patient Website.
- Real Patient Stories
Visit Today To Watch Real Patients
Talk About Their Experiences.
- Risks And Side Effects
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [8] and Canada, [9] and the European Union [5] to treat systemic lupus erythematosus and lupus nephritis. [10]
B-cell activating factor (BAFF) also known as tumor necrosis factor ligand superfamily member 13B and CD257 among other names, is a protein that in humans is encoded by the TNFSF13B gene. [ 5 ] [ 6 ] BAFF is also known as B Lymphocyte Stimulator (BLyS) and TNF- and APOL-related leukocyte expressed ligand (TALL-1) and the Dendritic cell-derived ...
nerve growth factor (NGF) [36] Y: pain associated with osteoarthritis in dogs [36] Begelomab [6] mab: mouse: DPP4: Belantamab mafodotin [5] Blenrep: mab: humanized: B-cell maturation antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus ...
He was involved in the discovery of B-cell activating factor (BAFF), also known as B Lymphocyte Stimulator (BLyS), a cytokine that stimulates the reproduction of B cells. This led to the development of a new drug, Belimumab, approved by the FDA in 2011 for systemic lupus erythematosus. [5]
Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Ads
related to: belimumab activating factor